Sökning: onr:"swepub:oai:DiVA.org:uu-109828" >
The Enterohepatic D...
The Enterohepatic Disposition of Rosuvastatin in Pigs and The Impact of Concomitant Dosing with Cyclosporine and Gemfibrozil
-
- Bergman, Ebba, 1977- (författare)
- Uppsala universitet,Institutionen för farmaci,Biopharmaceutics
-
- Lundahl, Anna (författare)
- Uppsala universitet,Institutionen för farmaci,Biopharmaceutics
-
- Fridblom, Patrik (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper
-
visa fler...
-
- Hedeland, Mikael (författare)
- Uppsala universitet,Avdelningen för analytisk farmaceutisk kemi
-
- Bondesson, Ulf (författare)
- Uppsala universitet,Avdelningen för analytisk farmaceutisk kemi
-
- Knutson, Lars (författare)
- Uppsala universitet,Institutionen för kirurgiska vetenskaper
-
- Lennernäs, Hans (författare)
- Uppsala universitet,Institutionen för farmaci,Biopharmaceutics
-
visa färre...
-
(creator_code:org_t)
- 2009-09-22
- 2009
- Engelska.
-
Ingår i: Drug Metabolism And Disposition. - : American Society for Pharmacology & Experimental Therapeutics (ASPET). - 0090-9556 .- 1521-009X. ; 37:12, s. 2349-2358
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The hepatobiliary transport and local disposition of rosuvastatin in pig was investigated, along with the impact of concomitant dosing with two known multiple transport inhibitors; cyclosporine and gemfibrozil. 80 mg rosuvastatin was administered as an intrajejunal bolus dose in Treatments I, II and III (TI, TII, and TIII, respectively; n=6 per treatment). Cyclosporine (300 mg) and gemfibrozil (600 mg) were administered in addition to the rosuvastatin dose in TII and TIII, respectively. Cyclosporine was administered as a two hour intravenous infusion and gemfibrozil as an intrajejunal bolus dose. In Treatment IV (TIV, n=4) was 5.9 mg rosuvastatin administered as an intravenous bolus dose. The study was conducted using a pig model, which enabled plasma sampling from the portal (VP), hepatic (VH) and femoral veins and bile from the common hepatic duct. The biliary recovery of the administered rosuvastatin dose was 9.0±3.5% and 35.7±15.6% in TI and TIV, respectively. Rosuvastatin was highly transported into bile as the median AUCbile/AUCVH ratio was 1770 (1640-11300) in TI. Gemfibrozil did not have an effect on the plasma pharmacokinetics of rosuvastatin, most likely because the unbound inhibitor concentrations did not exceed the reported IC50-values. However, cyclosporine significantly reduced the hepatic extraction of rosuvastatin (TI; 0.89±0.06, TII; 0.46±0.13) and increased the AUCVP and AUCVH by 1.6 and 9.1-fold, respectively. In addition, the biliary exposure and fe, bile were reduced by ≈50%. The strong effect of cyclosporine was in accordance with inhibition of sinusoidal uptake transporters, such as members of the OATP-family, rather than canalicular transporters.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)
Nyckelord
- rosuvastatin
- cyclosporine
- gemfibrozil
- transport inhibition
- biliary excretion
- hepatobiliary transport
- pharmacokinetics
- PHARMACY
- FARMACI
- Biopharmaceutics
- Biofarmaci
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas